CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer
Y Kiniwa, Y Miyahara, HY Wang, W Peng, G Peng… - Clinical cancer …, 2007 - AACR
Purpose: Although elevated proportions of CD4+ CD25+ regulatory T (Treg) cells have been
shown in several types of cancers, very little is known about the existence and function of …
shown in several types of cancers, very little is known about the existence and function of …
Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer
Despite the important role of Th17 cells in the pathogenesis of many autoimmune diseases,
their prevalence and the mechanisms by which they are generated and regulated in cancer …
their prevalence and the mechanisms by which they are generated and regulated in cancer …
Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer
S Kageyama, H Ikeda, Y Miyahara, N Imai… - Clinical Cancer …, 2015 - AACR
Purpose: Preparative lymphodepletion, the temporal ablation of the immune system, has
been reported to promote persistence of transferred cells along with increased rates of tumor …
been reported to promote persistence of transferred cells along with increased rates of tumor …
Safety and persistence of WT1-specific T-cell receptor gene− transduced lymphocytes in patients with AML and MDS
I Tawara, S Kageyama, Y Miyahara… - Blood, The Journal …, 2017 - ashpublications.org
Abstract Wilms' tumor 1 (WT1) is constantly expressed in leukemic cells of acute leukemia
and myelodysplastic syndrome (MDS). A T-cell receptor (TCR) that specifically reacts with …
and myelodysplastic syndrome (MDS). A T-cell receptor (TCR) that specifically reacts with …
“Default” generation of neonatal regulatory T cells
G Wang, Y Miyahara, Z Guo, M Khattar… - The Journal of …, 2010 - journals.aai.org
Abstract CD4+ Foxp3+ regulatory T (Treg) cells were shown to control all aspects of immune
responses. How these Treg cells develop is not fully defined, especially in neonates during …
responses. How these Treg cells develop is not fully defined, especially in neonates during …
Tumor-associated galectin-3 modulates the function of tumor-reactive T cells
W Peng, HY Wang, Y Miyahara, G Peng, RF Wang - Cancer research, 2008 - AACR
T cells play an important role in cancer immunosurveillance and tumor destruction.
However, tumor cells alter immune responses by modulating immune cells through antigen …
However, tumor cells alter immune responses by modulating immune cells through antigen …
HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan
S Kitano, S Kageyama, Y Nagata, Y Miyahara… - Clinical cancer …, 2006 - AACR
Purpose: We developed a complex of tumor antigen protein with a novel nanoparticle
antigen delivery system of cholesteryl pullulan (CHP). To target HER2 antigen, we prepared …
antigen delivery system of cholesteryl pullulan (CHP). To target HER2 antigen, we prepared …
[HTML][HTML] Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance
D Muraoka, N Seo, T Hayashi, Y Tahara… - The Journal of …, 2019 - Am Soc Clin Investig
Immune checkpoint inhibitors and adoptive transfer of gene-engineered T cells have
emerged as novel therapeutic modalities for hard-to-treat solid tumors; however, many …
emerged as novel therapeutic modalities for hard-to-treat solid tumors; however, many …
[HTML][HTML] Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of …
S Kageyama, H Wada, K Muro, Y Niwa, S Ueda… - Journal of translational …, 2013 - Springer
Background Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer
vaccines. This study evaluated the safety, immune responses and clinical outcomes of …
vaccines. This study evaluated the safety, immune responses and clinical outcomes of …
Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination
The recent success of chimeric antigen receptor (CAR)-T cell therapy for treatment of
hematologic malignancies supports further development of treatments for both liquid and …
hematologic malignancies supports further development of treatments for both liquid and …